Lutetium (177Lu) edotreotide
This is a peptide receptor radionuclide therapy (PRRT) medication used to treat certain types of neuroendocrine tumors. It works by delivering targeted radiation therapy to cancer cells that have specific receptors called somatostatin receptors. The medication consists of a radioactive substance (lutetium) attached to a molecule that binds to these specific receptors on tumor cells.

Best Standard of Care
This refers to the currently accepted and widely used treatments that doctors would typically prescribe for patients with neuroendocrine tumors. The specific treatment is chosen by the doctor from an approved list of treatment options based on what they believe would work best for each individual patient.

Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (GEP-NET) – A rare type of cancer that develops in specialized cells called neuroendocrine cells, which are found throughout the digestive system and pancreas. These tumors can form in the stomach, intestines, pancreas, or other parts of the digestive system. GEP-NETs can be categorized into different grades based on how quickly the cells divide, with Grade 2 and Grade 3 representing more aggressive forms of the disease. These tumors often produce excess hormones that can affect various body functions. The disease typically progresses gradually, though the rate varies depending on the tumor grade.